POOLED ANALYSIS OF 3 EUROPEAN CASE-CONTROL STUDIES OF EPITHELIAL OVARIAN-CANCER .3. ORAL-CONTRACEPTIVE USE

被引:133
作者
FRANCESCHI, S
PARAZZINI, F
NEGRI, E
BOOTH, M
LAVECCHIA, C
BERAL, V
TZONOU, A
TRICHOPOULOS, D
机构
[1] EUROPEAN CANC PREVENT ORG, BRUSSELS, BELGIUM
[2] MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY
[3] UNIV LONDON LONDON SCH HYG & TROP MED, EPIDEMIOL MONITORING UNIT, LONDON WC1E 7HT, ENGLAND
[4] UNIV LAUSANNE, INST SOCIAL & PREVENT MED, CH-1005 LAUSANNE, SWITZERLAND
[5] RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, EPIDEMIOL & CLIN TRIALS UNIT, OXFORD OX2 6HE, ENGLAND
[6] ATHENS MED SCH, DEPT HYG & EPIDEMIOL, GR-11527 ATHENS, GREECE
[7] HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA
关键词
D O I
10.1002/ijc.2910490112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between use of oral contraceptives (OCs) and other contraceptive methods and the risk of ovarian cancer was examined in a combined analysis of 3 hospital-based case-control studies conducted in Italy, the United Kingdom, and Greece, for a total of 971 ovarian cancer cases and 2,258 controls under age 65. Compared with never-users, the combined multivariate relative risk (RR) for ever-users was 0.6 (95% confidence interval, Cl = 0.4-0.8) and the estimates were consistent in the 3 datasets. The protection was also similar across strata of age and parity. Considering various measures of OC use, available in the Italian and British datasets only, the protection conveyed on ovarian cancer risk increased with the duration of use and persisted in the medium-long period: the RR in women reporting their last OC use greater-than-or-equal-to 15 years prior to diagnosis was 0.5 (95% Cl = 0.2-1.0). The risks in ever-users were appreciably lower in those women who reported their first OC use before 25 years of age (RR = 0.3 for first use before age 25, 0.8 for first use at age 25-34 and 0.7 at 35 years or after). Such findings emerged similarly from Italian and British data. This combined analysis, besides offering further quantitative estimates of the protective effects of OCs on ovarian cancer risk in European populations, provides useful insights into the time pattern of the relationship between OC use and ovarian carcinogenesis, suggesting that the protection persists for 15 years or more after cessation of use and may be larger for use at younger age.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 33 条
[1]  
BAKER RJ, 1978, GLIM SYSTEM
[2]  
BERAL V, 1988, LANCET, V2, P1331
[3]   RISK-FACTORS FOR OVARIAN-CANCER - A CASE CONTROL STUDY [J].
BOOTH, M ;
BERAL, V ;
SMITH, P .
BRITISH JOURNAL OF CANCER, 1989, 60 (04) :592-598
[4]  
Breslow NE, 1980, IARC SCI PUBLICATION, V1
[5]  
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, 1987, N Engl J Med, V316, P650
[6]  
CASAGRANDE JT, 1979, LANCET, V2, P170
[7]  
CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711
[8]   FACTORS AFFECTING THE ASSOCIATION OF ORAL-CONTRACEPTIVES AND OVARIAN-CANCER [J].
CRAMER, DW ;
HUTCHISON, GB ;
WELCH, WR ;
SCULLY, RE ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (17) :1047-1051
[9]  
DAY NE, 1980, JNCI-J NATL CANCER I, V64, P977
[10]  
GREENE MH, 1984, SEMIN ONCOL, V11, P209